Bloomberg Cites PHE Alzheimer’s Disease Study

A new PHE study, commissioned by the Alzheimer’s Association, investigates the potential savings of obtaining an earlier diagnosis. As reported in Bloomberg, PHE’s study demonstrated that an increase in early diagnosis of Alzheimer’s would lead to significant savings for the US—potentially up to $7.9 trillion over the lifetimes of everyone alive right now.

To read the details in Bloomberg, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.